コンテンツへスキップ
Merck
  • Binding to heparin triggers deleterious structural and biochemical changes in human low-density lipoprotein, which are amplified in hyperglycemia.

Binding to heparin triggers deleterious structural and biochemical changes in human low-density lipoprotein, which are amplified in hyperglycemia.

Biochimica et biophysica acta. Molecular and cell biology of lipids (2020-04-15)
Shobini Jayaraman, Olivia R Chavez, Antonio Pérez, Inka Miñambres, Jose Luis Sánchez-Quesada, Olga Gursky
要旨

Low-density lipoprotein (LDL) binding to arterial proteoglycans initiates LDL retention and modification in the arterial wall, triggering atherosclerosis. The details of this binding, its effectors, and its ramifications are incompletely understood. We combined heparin affinity chromatography with biochemical, spectroscopic and electron microscopic techniques to show that brief binding to heparin initiates irreversible pro-atherogenic remodeling of human LDL. This involved decreased structural stability of LDL and increased susceptibility to hydrolysis, oxidation and fusion. Furthermore, phospholipid hydrolysis, mild oxidation and/or glycation of LDL in vitro increase the proteolytic susceptibility of apoB and its heparin binding affinity, perhaps by unmasking additional heparin-binding sites. For LDL from hyperglycemic type-2 diabetic patients, heparin binding was particularly destabilizing and caused apoB fragmentation and LDL fusion. However, for similar patients whose glycemic control was restored upon therapy, LDL-heparin binding affinity was rectified and LDL structural stability was partially restored. These results complement previous studies of LDL binding to arterial proteoglycans and suggest that such interactions may produce a particularly pro-atherogenic subclass of electronegative LDL. In summary, binding to heparin alters apoB conformation, perhaps by partially peeling it off the lipid, and triggers pro-atherogenic LDL modifications including hydrolysis, oxidation, and destabilization. Furthermore, phospholipid lipolysis, mild oxidation and glycation of LDL in vitro strengthen its binding to heparin, which helps explain stronger binding observed in hyperglycemic LDL. Combined effects of hyperglycemia and heparin binding are especially deleterious but are largely rectified upon diabetes therapy. These findings help establish a mechanistic link between diabetes and atherosclerosis.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
トリプシン ウシ膵臓由来, TPCK Treated, essentially salt-free, lyophilized powder, ≥10,000 BAEE units/mg protein
Sigma-Aldrich
リパーゼ ブタ膵臓由来, Type II, ≥125 units/mg protein (using olive oil (30 min incubation)), 30-90 units/mg protein (using triacetin)
Sigma-Aldrich
フェニルメチルスルホニルフルオリド 溶液, ~0.1 M in ethanol (T)
Sigma-Aldrich
ヘパリン ナトリウム塩 from porcine intestinal mucosa, Grade I-A, ≥180 USP units/mg
Sigma-Aldrich
オレイン酸ナトリウム, ≥99%
Sigma-Aldrich
メチルグリオキサール 溶液, ~40% in H2O
Sigma-Aldrich
プラスミン ヒト血漿由来, lyophilized powder, ≥2.0 units/mg protein
Sigma-Aldrich
ヘパリン ナトリウム塩 from porcine intestinal mucosa, ≥180 USP units/mg
Sigma-Aldrich
スフィンゴミエリナーゼ Bacillus cereus由来, buffered aqueous glycerol solution, ≥100 units/mg protein (Lowry)
Sigma-Aldrich
Apolipoprotein E, human
Sigma-Aldrich
Myeloperoxidase, Human Polymorphonuclear Leukocytes, A lysosomal enzyme that catalyzes oxidations by hydrogen peroxide, including MPO-chloride-mediated killing of microbes and tumor cells, inactivation of chemotactic factors, and cross-linking of proteins.
Sigma-Aldrich
抗アポリポタンパク質E抗体, serum, Chemicon®
Sigma-Aldrich
ホスホリパーゼC Bacillus cereus由来, ≥200 units/mg protein
Sigma-Aldrich
Apolipoprotein C-III, human
Sigma-Aldrich
Matrix Metalloproteinase-12, Catalytic Domain ヒト, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), buffered aqueous glycerol solution